ICER issues final report and policy recommendations on acute treatments for migraine

ICER

25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans.

The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and economic value of three acute treatments for migraine: lasmiditan (Reyvow, Eli Lilly), rimegepant (Biohaven), and ubrogepant (Ubrelvy, Allergan). 

ICER’s report on these therapies was reviewed at the January 2020 public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder